title: Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series.
abstract: Unresectable cholangiocarcinoma is poorly responded to chemotherapy, especially for the case refractory to gemcitabine and cisplatin. Here, we tested whether high expression of thymidine phosphorylase (TP) can be a predictive biomarker for the indicator for gemcitabine and doxifluridine combination chemotherapy in the cholangiocarcinoma refractory to gemcitabine and cisplatin. Immunohistochemical staining for TP was performed with a biopsy specimen. We accepted the result as positive when more than 10% of cancer cells were stained with moderate intensity. Here, we report 2 cases of TP-positive cholangiocarcinoma well controlled with gemcitabine and doxifluridine combination chemotherapy, which had been refractory to the first line treatment with gemcitabine and cisplatin combination chemotherapy.
authors.affiliation: From the Department of Internal Medicine (MHK, WSL, S-IG, MJK, USL, HJC, H-GK); Department of Pathology (DCK, J-HL); and Department of Surgery, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, South Korea (KSB, JMC).
authors.forename: Myoung Hee
authors.initials: MH
authors.lastname: Kang
authors.forename: Won Sup
authors.initials: WS
authors.lastname: Lee
authors.forename: Se-Il
authors.initials: SI
authors.lastname: Go
authors.forename: Moon Jin
authors.initials: MJ
authors.lastname: Kim
authors.forename: Un Seok
authors.initials: US
authors.lastname: Lee
authors.forename: Hye Jung
authors.initials: HJ
authors.lastname: Choi
authors.forename: Dong Chul
authors.initials: DC
authors.lastname: Kim
authors.forename: Jeong-Hee
authors.initials: JH
authors.lastname: Lee
authors.forename: Hoon-Gu
authors.initials: HG
authors.lastname: Kim
authors.forename: Kyung Soo
authors.initials: KS
authors.lastname: Bae
authors.forename: Jae Min
authors.initials: JM
authors.lastname: Cho
mesh_terms: D000328:Adult; D001650:Bile Duct Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D001653:Bile Ducts, Intrahepatic; D014408:Biomarkers, Tumor / Q000097:blood; D018281:Cholangiocarcinoma / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D013939:Thymidine Phosphorylase / Q000097:blood*; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
chemical_list: D014408:Biomarkers, Tumor; D005467:Floxuridine; D003841:Deoxycytidine; D013939:Thymidine Phosphorylase; C025034:doxifluridine; D000093542:Gemcitabine